REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > Polycyclo Ring System Having A 1,2- Or 1,4-diazine As One Of The Cyclos Polycyclo Ring System Having A 1,2- Or 1,4-diazine As One Of The CyclosPolycyclo Ring System Having A 1,2- Or 1,4-diazine As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021428 - Immunomodulating heterocyclic compounds Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: wherein R1 and R3 independently represent H; F; CI; Br; —NO2; —CN; C1-C6 alkyl optionally substituted by F or Cl; or C1-C6 alkoxy optionally substituted by F; R4 represents a carboxylic acid group (—COOH) or an ester ... 01/11/07 - 20070010519 - New pyridazines as 11b-hsd1 inhibitors as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions. ... 12/28/06 - 20060293330 - Hiv replication inhibiting purine derivatives provided that when A represents a radical of formula (a) then B represents a radical of formula (b) and when A represents a radical of formula (b) then B represents a radical of formula (a). ... 12/21/06 - 20060287324 - Bicyclic heterocycles as cannabinoid-1 receptor modulators including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein. ... 12/21/06 - 20060287323 - Azabicyclic heterocycles as cannabinoid receptor modulators including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3 and R4 are described herein. ... 12/14/06 - 20060281750 - Heteroaryl 11-beta-hydroxysteroid dehydrogenase type i inhibitors or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein. ... 12/07/06 - 20060276477 - Treatment method for anemia The present invention relates to improved methods for treating anemia. Methods and compounds useful for treating anemia, wherein the anemia treatment is associated with a lower risk of thrombosis or hypertension compared to that observed with rhEPO therapy, are provided. ... 11/30/06 - 20060270678 - Pyrrolopyridazine derivatives The invention relates to compound of the formula (I) or its salt, in which R1, R2, R3 and R4 are as defined in the description, their use of as medicament, the process for their preparation and use for the treatment of PDE-IV or TNF-α mediated diseases. ... 11/30/06 - 20060270677 - Method for the treatment of noise phobia in companion animals The present invention provides a method for the non-sedative treatment of noise phobia in a companion animal, particularly a dog, which comprises providing said animal with a therapeutically effective amount of N-methyl-N-[3-(3-methyl-1,2,4-triazolo-[4,3-b]pyridazin-6-yl)phenyl]acetamide or 7-(3-pyridyl)pyrazolo[1,5-a]pyrimidine-3-carbonitrile. ... 11/23/06 - 20060264439 - Inhibitors of polo-like kinase-1 including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein ring moiety A, R1, R2, R3, R4, R5, R6, R7, R8 and X are as defined herein. Also disclosed are compositions comprising such compounds and methods of using same. ... 11/16/06 - 20060258660 - Stabilization of hypoxia inducible factor (hif) alpha The present invention relates to methods of stabilizing the alpha subunit of hypoxia inducible factor (HIF). The invention further relates to methods of preventing, pretreating, or treating conditions associated with HIF, including ischemic and hypoxic conditions. Compounds for use in these methods are also provided. ... 11/16/06 - 20060258659 - Heterocyclic compounds and their uses as therapeutic agents This invention is directed to heterocyclic compounds that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed. ... 11/09/06 - 20060252757 - Cinnoline compounds This invention relates generally to cinnoline-based modulators of Liver X receptors (LXRs) and related methods. ... 11/02/06 - 20060247243 - Sulfonylaminovalerolactams and derivatives thereof as factor xa inhibitors or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa. ... 10/26/06 - 20060241116 - 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation and therapeutic use in which X represents a hydrogen or halogen atom; R1 represents a hydrogen atom or a (C1-C4)alkyl group; R2 and R3 each represent, independently of one another, a hydrogen atom or a (C1-C4)alkyl group or else R2 and R3 form, with the nitrogen atom which carries them, a pyrrolidinyl, piperidinyl, ... 10/26/06 - 20060241115 - Compounds and methods of use Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention ... 10/05/06 - 20060223809 - Novel compounds The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where ... 10/05/06 - 20060223808 - Spirocyclic thrombin receptor antagonists represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, En, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined ... 10/05/06 - 20060223807 - Therapeutic methods for type i diabetes The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying β-cells (i.e., insulin-producing cells in the pancreatic islets of Langerhans) by inhibition of JNK2, selective inhibition of JNK2, or inhibition of ... 09/28/06 - 20060217384 - Bicyclic and tricyclic heteroaromatic compounds and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes ... 09/28/06 - 20060217383 - 1-/2-substituted-1h/-2h-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compound, process for the preparation thereof and pharmaceutical composition comprising the same The present invention relates to 1-/2-substituted-1H/-2H-[1,2,3]triazolo[4,5-g]phthalazine-4,9-dione compounds and their pharmaceutically acceptable salts, a process for preparing the compounds and a pharmaceutical composition comprising the compounds. The compounds are shown to effectively inhibit cell proliferation and are thus expected to be used for treatment or prevention or treatment of various cancers ... 08/24/06 - 20060189617 - Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists. ... 08/24/06 - 20060189616 - 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists. ... 08/03/06 - 20060173009 - Agent inducing increase in bone mass Osteoporosis and the like metabolic bone diseases have a high frequency of causing lumbago and the like pains and bone fracture, due to lowering of the bone strength caused by the reduction of bone mass. Accordingly, great concern has been directed toward the creation of a drug which can increase ... 07/27/06 - 20060166999 - Use of microsomal triglyceride transfer protein (mtp) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (pptrl) The invention relates to the use of inhibitors of the microsomal triglyceride transfer protein (MTP) for reducing the number of postprandial triglyceride-rich lipoprotein particles (ppTRL) or for reducing their decomposition products i.e. the cholesterol-rich ‘small remnant particle’ (remnants). Said particles are associated with apolipoprotein B-48 (ApoB-48) and are designated as ... 07/27/06 - 20060166998 - Pyrrolo[1,2-b]pyridazine compounds and their uses including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me. ... 07/27/06 - 20060166997 - Phenylglycinamide derivatives useful as anticoagulants The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or ... 07/27/06 - 20060166996 - Phthalazine derivatives as phosphodiesterase 4 inhibitors Compounds of formula I wherein R and R1 are as defined in the description. The compounds of formula I are PDE 4 inhibitors. ... 07/27/06 - 20060166995 - Piperidine-n-oxide-derivatives in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors. ... 07/20/06 - 20060160814 - Phosphodiesterase 10 inhibitors wherein R1—R3 and R15—R18 are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. ... 07/20/06 - 20060160813 - Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors in which the substituents have the meanings as indicated in the description, are novel effective PDE4 inhibitors. ... 07/13/06 - 20060154930 - Substituted amino heterocycles as vr-1 antagonists for treating pain The present invention provides compounds of formula I: in which: one of T1 and T4 is N and the other is C; T2 and T3 are independently N or C(CH2)nR2; X, Y and Z are independently N or C(CH2)nR3; R1 is Ar1 or R1 is C1-6alkyl optionally substituted with one ... 07/13/06 - 20060154929 - Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds 6H-pyrrolo[3,4-d]pyridazine compounds and methods of their use of as ligands of voltage gated calcium channels (VGCC), useful in the treatment of neuropathic pain, and psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive ... 07/06/06 - 20060148807 - Pyrrolo[1,2b]pyridazine compounds and their uses including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me. ... 07/06/06 - 20060148806 - Opthalmic compositions for treating ocular hypertension A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor. ... 07/06/06 - 20060148805 - Opthalmic compositions for treating ocular hypertension This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect ... 07/06/06 - 20060148804 - Pde4 inhibitors for the treatment of neoplasms of lymphoid cells The invention relates to the use of certain PDE4 inhibitors alone or in combination with one or more differentiation inducing agents and/or an agent effective in raising intracellular concentrations of cAMP or a stable analogue of cAMP in the preparation of pharmaceutical compositions for the treatment of neoplasms of lymphoid ... 07/06/06 - 20060148803 - Substituted peptides useful in the treatment of alzheimer's disease Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I), wherein Ar, W, Z, Q, R1, U, and L, are as herein defined. ... 06/29/06 - 20060142293 - Phthalazinone derivatives RN is selected from hydrogen, optionally substituted C1-7 alkyl, C3-20 heterocyclyl, and C5-20 aryl, hydroxy, ether, nitro, amino, amido, thiol, thioether, sulfoxide and sulfone. ... 06/15/06 - 20060128710 - Antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A, N, X, Y, R1, R2 and R3 are as defined in the specification. These compounds are particularly useful in the treatment of pain, inflammatory hyperalgesia, and urinary dysfunctions, such as bladder overactivity and urinary incontinence. ... 06/08/06 - 20060122185 - Bicyclic inhibitors of rho kinase The present invention relates to compounds useful as inhibitors of protein kinases, particularly of ROCK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. ... 06/01/06 - 20060116379 - Compounds exhibiting type x spla2 inhibiting effect wherein R20 is —CH2COOH and the like; R21 is —COCONH2 and the like; R22 is C4-C6 alkyl; and the like; R23 is —CH2—R18 wherein R18 is aryl and the like; R24 is hydrogen or C1-C6 alkyl and the like; an optical active compound, a prodrug thereof, or a pharmaceutically acceptable ... 06/01/06 - 20060116378 - Fused heterocyclic isoxazoline derivatives and their use as anti-derpressants The invention concerns fused heterocyclic isoxazoline derivatives of Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivatives fused to a heterocyclic ring system via the 6-membered ring of ... 05/25/06 - 20060111355 - Gonadotropin releasing hormone receptor antagonists The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Luteinizing Hormone Releasing Hormone) receptor antagonists. ... 05/18/06 - 20060106020 - Tetracyclic inhibitors of janus kinases The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer. ... 05/04/06 - 20060094723 - Composition comprising a pde4 inhibitor and a pde5 inhibitor The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) is detrimental. ... 05/04/06 - 20060094722 - Combination drug The present invention provides pharmaceutical agents comprising a dipeptidyl peptidase IV (DPPIV) inhibitor and a biguanide agent in combination, which enhance the effects of active circulating glucagon-like peptide-1 (GLP-1) and/or active circulating glucagon-like peptide-2 (GLP-2). ... 04/27/06 - 20060089359 - Phthalazinone derivatives their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates are disclosed. Also disclosed are methods for the preparation of the above-mentioned compounds, pharmaceutical compositions containing them, as well as the use of the above-mentioned compounds in the treatment, control or prevention of illnesses such as cancer. ... 04/20/06 - 20060084653 - Beta-sheet mimetics and composition and methods relating thereto including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A′, B, X, Y, R2, R3, R4 and R5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such ... 04/20/06 - 20060084652 - Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents process for their production, and their use as anti-inflammatory agents. ... 04/20/06 - 20060084651 - Chemical compounds The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity. ... 04/13/06 - 20060079527 - Piperazine derivatives having sst1 antagonistic activity The invention provides compounds of formula (I), wherein X, R1 and R2 are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals. ... 04/06/06 - 20060074087 - 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also ... 03/30/06 - 20060069097 - Pyradazine compounds as gsk-3 inhibitors The present invention relates generally to inhibitors of the kinases, such as GSK3, and more particularly to fused pyradazine compounds and methods of their use. ... 03/23/06 - 20060063767 - Phthalazinone derivatives where Q is O or S. ... 03/16/06 - 20060058306 - Solubilized topoisomerase poison agents A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic ... 03/16/06 - 20060058305 - 3-phenyl-cinnoline homologue and antitumor agent containing the same The present invention relates to a 3-phenyl-cinnoline analogue or a physiologically acceptable salt thereof, and a cell proliferation inhibitor and an antitumor agent comprising the same, as an active ingredient. ... 03/09/06 - 20060052381 - Solubilized topoisomerase poisons A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic ... 03/09/06 - 20060052380 - Novel compounds The invention relates to thienopyridazinones of formula (I): wherein: R1 is C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl which is optionally substituted by C1-6 alkyl, each of the above being optionally substituted by one or more halogen atoms; R2 is C1-6 alkyl; R3 is a group CO-G or SO2-G where ... 03/02/06 - 20060046988 - Methoprene formulations for the control of tick infestations The present invention relates to a composition and process, in particular for controlling ticks on animals, characterized in that the composition includes, on the one hand, at least one compound of IGR (insect growth regulator) type, in doses and proportions which are parasiticidally effective on ticks, in a fluid vehicle ... 02/16/06 - 20060035897 - Trifluoromethyl substituted benzamides as kinase inhibitors pharmaceuticals comprising these compounds, their use as or for the manufacture of pharmaceuticals, particularly as inhibitors of protein kinases, especially of ephrin receptor kinases, and/or the treatment of a condition, disorder or disease state mediated by a protein kinase activity and/or a proliferative disease, methods of treatment comprising administering the ... 02/09/06 - 20060030564 - Inhibitors of akt activity The present invention is directed to compounds comprising a triazolo[4,3-b]pyridazine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention. ... 02/02/06 - 20060025417 - Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives R1 represents a hydrogen atom, a C1-6 alkyl group or a halogen atom; R2 represents a hydrogen atom, a C1-6 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom, a hydroxyl group, a C1-4 alkoxy group; a C1-2 perhalogenated alkyl group, a benzyl group, a ... 01/19/06 - 20060014748 - 2-nh-heteroarylimidazoles with antibacterial activity are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections. ... 01/19/06 - 20060014747 - Ortho-substituted anthranilic acid amides and their use as pharmaceutical agents Ortho-substituted anthranilic acid amides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. ... 01/19/06 - 20060014746 - Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I or Formula II in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes ... 01/05/06 - 20060004009 - Ethylenediamine derivatives or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents —CO— or —SO2—, and a medicine which comprises the compound and is useful for thrombosis and embolism. ... 01/05/06 - 20060004008 - Topoisomerase-targeting agents the bond represented by — is a single bond or a double bond, and R1-R5, X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds ... 12/29/05 - 20050288291 - Modulation of cell fates and activities by phthalazinediones Phthalazinediones that function as intracellular redox modulators are useful in treating cells in various disease states where intracellular redox status is impaired. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, ... 12/15/05 - 20050277644 - Pyridine analogs as c5a antagonists The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of C5a-mediated diseases using the novel compounds described ... 12/08/05 - 20050272734 - Benzothiazole antiviral agents The invention encompasses a series of benzothiazole compounds which inhibit HIV entry and are useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for using these compounds. ... 11/24/05 - 20050261297 - Nitrogen-containing heterocyclic compound As a result of an effort made by us for the purpose of developing a therapeutic agent having a bone formation-stimulating effect by promoting the functions of osteoblasts, the present inventors discovered that a certain nitrogen-containing heterocyclic compound exhibits a potent bone formation-stimulating effect on the osteoblast and thus can ... 11/24/05 - 20050261296 - Indole, azaindole and related heterocyclic n-substituted piperazine derivatives —W— is ... 11/17/05 - 20050256124 - Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R5, Het, X and Cyc are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof. ... 10/27/05 - 20050239786 - Triazole derivatives as tachykinin receptor antagonists This application relates to a compound of Formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and its use as an inhibitor of the NK-1 subtype of tachykinin receptors, as well as a process for its preparation and intermediates therefor. (I) wherein: D is a C1-C3 alkane-diyl; R1 ... 10/20/05 - 20050234062 - Phthalazinone-piperidino-derivatives as pde4 inhibitors in which the given substituents have the meanings as given in the description, are novel effective PDE4 inhibitors. ... 10/20/05 - 20050234061 - Substituted amides Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, ... 10/13/05 - 20050227986 - Vanilloid receptor ligands and their use in treatments and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic ... 09/22/05 - 20050209238 - Method for treating ocular neovascular diseases The invention relates to the use of certain phthalazines in the preparation of medicaments for the treatment of ocular neovascularization. ... 09/22/05 - 20050209237 - Method for decreasing capillary permeability in the retina Disclosed herein are methods for decreasing or attenuating an increase in capillary permeability in the retina in a subject in need of such treatment, comprising administering a composition comprising an amount of a phthalazine derivative or a salt thereof to a subject suffering from excessive or pathological capillary permeability in ... 09/22/05 - 20050209236 - Heteroaryl carboxylic acid amides The invention relates to novel heteroaryl carboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. ... 09/15/05 - 20050203095 - Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions wherein R1 and R4 are defined as in claim 1, the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV). ... 09/15/05 - 20050203094 - 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors The present invention provides 2-[5-(5-carbamimidoyl-1H-heteroaryl)]-6-hydroxy-biphenyl-3-yl derivatives of formula (I): I That are Factor VIIa and Xa inhibitors ... 09/01/05 - 20050192281 - Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders Disclosed are aryl, heteroaromatic and bicyclic aryl nitrone compounds and pharmaceutical compositions containing such derivatives. The disclosed compositions are useful for preventing and/or treating pain, neurodegenerative, autoimmune and inflammatory diseases or conditions in mammals. ... 08/25/05 - 20050187220 - Substituted 4-aminocyclohexanols Substituted 4-aminocyclohexanols, processes for their preparation, pharmaceutical compositions comprising these compounds and to the use of substituted 4-aminocyclohexanols in the preparation of pharmaceutical compositions for the treatment of various indications, especially pain as well as the treatment of these indications. ... 08/18/05 - 20050182060 - 2-substituted and 4-substituted aryl nitrone compounds The present invention provides aryl nitrones, compositions comprising the same and methods of their use for the treatment or prevention of oxidative, ischemic, ischemia/reperfusion-related and chemokine mediated conditions. ... 08/18/05 - 20050182059 - Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives Novel imidazo[1,2-b]pyridazine compounds useful for controlling parasites in animals and methods of treatment of parasite infestation in animals using the compounds are disclosed. ... 08/04/05 - 20050171110 - Azabicyclic heterocycles as cannabinoid receptor modulators including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R4, R5, m and n are described herein. ... 08/04/05 - 20050171109 - Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents The invention relates to tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents. ... 08/04/05 - 20050171108 - Novel process for producting imidazo[1,2-b]pyridazine derivative (wherein X represents halogeno or lower alkyl optionally substituted by halogeno; Y represents hydrogen or SO2N═CH—NR1R2; and Z represents halogeno or OSO2R3) with an organometallic compound in the presence of a transition metal catalyst. The derivative is useful as an intermediate for herbicides. ... 07/28/05 - 20050165024 - Urea derivatives as kinase modulators The invention provides methods and compositions for treating conditions mediated by various kinases wherein derivatives of urea compounds are employed. The invention also provides methods of using the compounds and/or compositions in the treatment of a variety of diseases and unwanted conditions in subjects. ... 07/21/05 - 20050159420 - Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders. ... 07/21/05 - 20050159419 - Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of ... 07/14/05 - 20050153968 - Monocyclic n-aryl hydantoin modulators of androgen receptor function The present invention relates to novel compounds useful in the treatment of androgen receptor associated conditions, such as age-related diseases, pharmaceutical compositions containing at least one of the compounds of the present invention and methods of treating a patient in need of therapy for an androgen receptor associated condition by ... 07/14/05 - 20050153967 - Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo'1,5-bipyridazine in nanoparticulate form and pharmaceutically acceptable salts thereof, in which the compound is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients. ... 06/30/05 - 20050143381 - Azabicyclic heterocycles as cannabinoid receptor modulators including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein. ... 06/23/05 - 20050137200 - Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use in which R1 to R7 have the meanings stated in the claims, act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. They are therefore suitable as novel antiarrhythmic ingredients, such as ... 06/23/05 - 20050137199 - Aza-quinolinol phosphonate integrase inhibitor compounds Ar is aryl or heteroaryl connecting R6 to L. L is a bond or a linker connecting a ring atom of Ar to N. The ring atoms, X1-X5 may be N, substituted nitrogen, or substituted carbon, and form rings. The compounds include at least one phosphonate group covalently attached at ... 06/23/05 - 20050137198 - Stable hydrazalazine pharmaceutical compositions The present invention relates to stable and highly purified stable hydralazine hydrochloride compositions and stable hydralazine-containing pharmaceutical compositions. A sterile aqueous injectable pharmaceutical composition suitable for parenteral administration is described comprising a therapeutically effective dose of hydralazine hydrochloride in a pharmaceutically acceptable carrier or diluent wherein said hydralazine hydrochloride is ... 06/16/05 - 20050130976 - Bicyclic inhibitors of mek and methods of use thereof and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R8, R9 and R10, W, X, and Z are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are ... 06/16/05 - 20050130975 - Stable pharmaceutical compositions where R1 and R2 are independently H, branched or straight chain alkyl having from 1 to about 7 carbon atoms, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl, substituted or unsubstituted alkylcycloalkyl, lower alkenyl or R1 and R2 together form part of a substituted or unsubstituted ... 06/16/05 - 20050130974 - Benzothiazole compositions and their use as ubiquitin ligase inhibitors This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention ... 06/09/05 - 20050124623 - Diazaindole-dicarbonyl-piperazinyl antiviral agents compositions thereof and their use for treating HIV infection. ... 06/09/05 - 20050124622 - Compounds and methods for the treatment of pain 2-substituted 7-chloro-4-hydroxy-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione compounds, pharmaceutical compositions and methods for the treatment of pain are disclosed. ... 06/02/05 - 20050119266 - Pyrrolidine and piperidine derivatives as factor xa inhibitors The present application describes pyrrolidine and piperidine derivatives or pharmaceutically acceptable salt forms thereof. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa. ... ### FreshPatents.com Support |